Table 2.
Outcomes in the entire cohort.
| Outcome | All patients n = 1540 (100%) | Received corticosteroids n = 688 (45%) | Did not receive corticosteroids n = 852 (55%) | p-value |
|---|---|---|---|---|
| Death – no. (%)* | 387 (25) | 122 (18) | 265 (31) | <.001 |
| Death in patients on mechanical ventilation – no. (%) n = 410 |
184 (45) | 72 n = 206 (25) |
112 n = 204 (55) |
<.001 |
| Length of stay in survivors, days – median (IQR)† n = 1153 |
7 (5–14) |
8 (5–16) n = 566 |
7 (5–13) n = 587 |
.054 |
| Use of mechanical ventilation during follow-up – no. (%) n = 1313 |
183 (14) | 87 (15) n = 569 |
96 (13) n = 744 |
.216 |
| Time from admission to mechanical ventilation, days – median (IQR) n = 183 |
4 (2–5) | 5 (3–7) | 3 (2–4) | .001 |
| Duration of mechanical ventilation in survivors, days – median (IQR) n = 226 |
13 (9–20) | 13 (8–20) n = 134 |
14 (11–20) n = 92 |
.406 |
| Hospital-acquired infection – no. (%) | 221 (14) | 139 (20) | 82 (10) | <0.001 |
| Hospital-acquired infection in patients on mechanical ventilation – no. (%) n = 410 |
201 (49) | 125 (61) n = 206 |
76 (37) n = 204 |
<0.001 |
| Hospital-acquired/ventilation-associated pneumonia – no. (%) | 158 (10) | 103 (15) | 55 (7) | <.001 |
| Bloodstream infection – no. (%)‡ | 66 (4) | 34 (5) | 32 (4) | .258 |
| COVID-19-associated pulmonary aspergillosis – no. (%)‡ | 25 (2) | 14 (2) | 11 (1) | .311 |
| Candidaemia – no. (%)‡ | 17 (1) | 9 (1) | 8 (1) | .625 |
IQR, interquartile range.
*Unless otherwise specified, dichotomous outcome frequencies were compared using χ2.
†Quantitative variables were compared using two-sample rank-sum tests.
‡Dichotomous outcome frequencies were compared using Fisher’s exact test.